EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 40 Years to 80 Years
- Sex
- All sexes
- Healthy volunteers
- Accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: Blood draws, Questionnaires
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening."
- "The research study procedures include screening for eligibility, in-clinic visits, blood tests, and an optional questionnaire and/or focus group."
- "It is expected that about 1000 people will participate in the blood sample collection, 100 individuals in the survey, and 20 individuals in the focus groups."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age): * Non-tobacco using (currently) * Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx. * East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian * Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, Filipino * Latinx includes those who self-identify as a person of Central or South American and the Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain * Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean * Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish. Inclusion Criteria (Aims 1, 2, and 3) for Group 2 (40 through 49 years of age): * Non-tobacco using (currently) * Self-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met: * Family history of EGFR positive LC L858R or exon 19 * Personal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago * History of TB, asthma requiring daily inhaled corticosteroids or chronic bronchitis * Symptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, dyspnea or worsening dyspnea * Excluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirus infection, runny nose, sore throat, productive cough with green or yellow sputum * Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean * Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish. Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2: * Having had a chest CT scan in the last 3 years or having an anticipated chest CT scan during the enrollment period. * Having a current cancer or history of cancer within the last 5 years, excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ. * More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use * Adults unable to provide informed consent * Individuals \<40 years of age * Prisoners * Pregnant women * Personal diagnosis of lung cancer * Not able to be compliant with study requirements
Study sites (6)
MA
- Beth Israel Deaconess Medical Center · Boston, MA 02215Daniel Costa, MD, PhD · Study contact · 617-667-7000 · dbcosta@bidmc.harvard.eduDaniel Costa, MD, PhD · Principal investigatorMore trials in Boston
- Dana-Farber Cancer Institute · Boston, MA 02215Narjust Florez, MD · Study contact · 617-582-7335 · narjust_florez@dfci.harvard.eduNarjust Florez, MD · Principal investigatorMore trials in Boston
- Massachusetts General Hospital · Boston, MA 02215Lecia Sequist, MD, MPH · Study contact · 617-726-5130 · lvsequist@mgb.orgLecia Sequist, MD, MPH · Principal investigatorMore trials in Boston
- Dana-Farber Cancer Institute at Steward St. Elizabeth's · Brighton, MA 02135Alys Malcolm, MD · Study contact · 617-632-4595 · alys_malcolm@dfci.harvard.eduAlys Malcolm, MD · Principal investigatorMore trials in Brighton
- Dana-Farber Cancer Instiute Merrimack Valley · Methuen, MA 01844Pedro Sanz-Altamira, MD · Study contact · 978-620-2020 · pedro_sanz-altamira@dfci.harvard.eduPedro Sanz-Altamira, MD · Principal investigatorMore trials in Methuen
- Dana-Farber Cancer Institute South Shore · South Weymouth, MA 02190Shail Maingi, MD · Study contact · 781-624-5000 · shail_maingi@dfci.harvard.eduShail Maingi, MD · Principal investigatorMore trials in South Weymouth